We are live on ! Find out more
A

Abingworth Portfolio holdings

AUM $307M
1-Year Est. Return 93.47%
This Fund
S&P 500
This Quarter Est. Return
+5.42%
1 Year Est. Return
+93.47%
3 Year Est. Return
+184.38%
5 Year Est. Return
+342.7%
10 Year Est. Return
–
AUM
$138M
AUM Growth
-$6.42M
Cap. Flow
-$4.09M
Cap. Flow %
-2.97%
Top 10 Hldgs %
92.68%
Holding
18
New
–
Increased
–
Reduced
2
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
CBAY
Cymabay Therapeutics
CBAY
+$3.38M
2
CRSP icon
CRISPR Therapeutics
CRSP
+$390K
3
INNL
Innocoll Holdings plc Ordinary Shares
INNL
+$322K

Sector Composition

Rank Sector Weight
1 Healthcare 97.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRSP icon
1
CRISPR Therapeutics
CRSP
$4.73B
$45.8M 33.18%
1,951,359
-20,548
-1% -$390K
SIEN
2
DELISTED
Sientra, Inc.
SIEN
$30.9M 22.35%
219,901
– –
PRTK
3
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$18.6M 13.5%
1,041,131
– –
CBAY
4
DELISTED
Cymabay Therapeutics
CBAY
$10.6M 7.65%
1,147,077
-395,645
-26% -$3.38M
OBSV
5
DELISTED
ObsEva SA Ordinary Shares
OBSV
$4.29M 3.11%
440,000
– –
ONCT
6
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
$4.28M 3.1%
2,423
– –
TARA icon
7
Protara Therapeutics
TARA
$220M
$3.73M 2.7%
50,447
– –
CHMA
8
DELISTED
Chiasma, Inc. Common Stock
CHMA
$3.43M 2.49%
2,080,595
– –
CASC
9
DELISTED
Cascadian Therapeutics, Inc.
CASC
$3.42M 2.48%
925,000
– –
CLLS
10
Cellectis
CLLS
$277M
$2.92M 2.11%
100,000
– –
DERM
11
DELISTED
Dermira, Inc.
DERM
$1.95M 1.41%
70,000
– –
OCGN icon
12
Ocugen
OCGN
$416M
$1.8M 1.31%
14,815
– –
RARE icon
13
Ultragenyx Pharmaceutical
RARE
$2.45B
$1.77M 1.28%
38,100
– –
ADAP
14
DELISTED
Adaptimmune Therapeutics
ADAP
$1.67M 1.21%
250,000
– –
IMDZ
15
DELISTED
Immune Design Corp.
IMDZ
$1.37M 1%
352,300
– –
AUPH icon
16
Aurinia Pharmaceuticals
AUPH
$1.91B
$1.14M 0.83%
252,129
– –
EVAR
17
DELISTED
Lombard Medical, Inc.
EVAR
$399K 0.29%
3,473,452
– –
INNL
18
DELISTED
Innocoll Holdings plc Ordinary Shares
INNL
– –
-537,235
Closed -$322K

Similar funds

AAM
Arabesque Asset Management London, United Kingdom $296M AUM 15.19% 1-Year Est. Return
EP
Equius Partners Novato, California $324M AUM 8.27% 1-Year Est. Return
LDFR
Lehman & Derafelo Financial Resources Media, Pennsylvania $337M AUM 8.16% 1-Year Est. Return
MPAM
Monarch Partners Asset Management Boston, Massachusetts $339M AUM 2.52% 1-Year Est. Return
MAG
Mass Ave Global New York $342M AUM 20.58% 1-Year Est. Return
CDIA
Capital Directions Investment Advisors Atlanta, Georgia $268M AUM 20.15% 1-Year Est. Return
GTCM
Gyon Technologies Capital Management Denville, New Jersey $267M AUM 11.62% 1-Year Est. Return
ACMV
August Capital Management VII Palo Alto, California $265M AUM 26.86% 1-Year Est. Return

Abingworth's Q4 2017 Portfolio in Review

As of Q4 2017, Abingworth held 18 positions worth $138M, down 4.4% from $144M the previous quarter. Its ten largest holdings account for 93% of the portfolio.

Abingworth's Q4 2017 filing shows 2 reduced and 1 closed positions. The largest sale was Cymabay Therapeutics, an estimated $3.38M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 95% a quarter earlier.

  • Abingworth's biggest Q4 2017 reduction was Cymabay Therapeutics, cutting an estimated $3.38M.
  • Abingworth fully exited Innocoll Holdings plc Ordinary Shares in Q4 2017, selling an estimated $322K.
  • Abingworth's ten largest holdings make up 93% of its $138M portfolio in Q4 2017.
  • Abingworth opened 0 new positions and closed 1 in Q4 2017.
  • Abingworth's portfolio value fell 4.4% quarter-over-quarter to $138M.

Based on Abingworth's 13F filing for Q4 2017, filed 14 Feb 2018.